Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2023 Jan-Mar;69(1):46-49.
doi: 10.4103/jpgm.JPGM_1335_20.

Cefoperazone/sulbactam-induced hemolytic anemia

X M Sun  1 , L H Liu  1 , Q Wu  2 , H G Wang  1
Affiliations
Case Reports

Cefoperazone/sulbactam-induced hemolytic anemia

X M Sun et al. J Postgrad Med. 2023 Jan-Mar.

Abstract

Drug-induced hemolytic anemia (DIHA) is a rare complication of drug therapy and usually underdiagnosed. Cefoperazone/sulbactam is a compound prepared from the third generation of cephalosporin and β-lactamase inhibitor. There are limited data of DIHA induced from cefoperazone/sulbactam. A 93-year-old female patient, who had an operation on the biliary tract 3 months ago, was admitted to our hospital with an abdominal infection. After cefoperazone/sulbactam was given as anti-infection treatment, the patient developed hemolytic anemia on the third day. Cefoperazone/sulbactam was discontinued and replaced with meropenem. Subsequently the level of red blood cells, hemoglobin, and hematocrit returned to normal. Clinicians should pay attention to monitoring the possible adverse reactions during the use of cefoperazone/sulbactam and should be aware of the occurrence of DIHA, so as to give timely treatment.

Keywords: Adverse reactions; cefoperazone; drug-related side effects; hemolytic anemia; sulbactam.

PubMed Disclaimer

Conflict of interest statement

None

Figures

Figure 1
Figure 1
Changes in blood test reports during the use of cefoperazone/sulbactam (the left side of the arrow) and after withdrawal of it, replaced by meropenem (the right side of the arrow) [a-f]
Figure 2
Figure 2
Changes of serum indirect bilirubin (IBIL) during the use of cefoperazone/sulbactam (the left side of the arrow) and after withdrawal of it, replaced by meropenem (the right side of the arrow)
See this image and copyright information in PMC

Comment in

References

    1. Iakovlev VP. [Sulperazone--a combined form of cefoperazone with sulbactam] Antibiot Khimioter. 1995;40:55–70. - PubMed
    1. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30:239–45. - PubMed
    1. Harcke SJ, Rizzolo D, Harcke HT. G6PD deficiency: An update. JAAPA. 2019;32:21–6. - PubMed
    1. Garratty G. Immune hemolytic anemia associated with drug therapy. Blood Rev. 2010;24:143–50. - PubMed
    1. Arndt PA, Leger RM, Garratty G. Positive direct antiglobulin tests and haemolytic anaemia following therapy with the beta-lactamase inhibitor, tazobactam, may also be associated with non-immunologic adsorption of protein onto red blood cells. Vox Sang. 2003;85:53. - PubMed

Publication types